Albireo Pharma (NASDAQ:ALBO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States. “
Other equities research analysts also recently issued reports about the stock. Wedbush reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Wednesday, January 3rd. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Friday, November 17th. Roth Capital started coverage on shares of Albireo Pharma in a research report on Wednesday, November 15th. They issued a “buy” rating and a $92.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating on shares of Albireo Pharma in a research report on Thursday, October 26th. Finally, ValuEngine downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $54.50.
In other news, major shareholder Plc Astrazeneca sold 500,000 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $21.40, for a total transaction of $10,700,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 22.30% of the stock is owned by corporate insiders.
About Albireo Pharma
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.